Head-to-head evidence
ABM-1310 vs Vemurafenib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: BRAF (V600 mutant) · full Non-Small Cell Lung Cancer pipeline
ABM-1310
Developed by ABM Therapeutics Corporation
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Vemurafenib
Marketed by Roche
NCT02314481 · Phase 2 · completed
This is a non-randomized, single-group study without blinding or a comparator arm, with 50 participants distributed across several treatment groups. Its primary endpoints are progression-free and overall survival, but results are not posted, so there is no reported comparison showing whether vemurafenib was effective.
Next expected readout: November 2026 · NCT04302025 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABM-1310's landscape · Vemurafenib's landscape